Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805233 · ClinicalTrials.gov registry record · Phase 2
Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00805233 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 30 participants.
The verdict
NCT00805233, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone.
Interventions
- DRUG combination ranibizumab + bromfenac
- DRUG ranibizumab injection alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00805233
The ClinicalTrials.gov registry entry for NCT00805233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which combination ranibizumab + bromfenac is the first listed.
NCT00805233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00805233 about?
NCT00805233 is a clinical study titled "Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration". This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone.
What is the current status of trial NCT00805233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00805233?
The interventions under investigation include: combination ranibizumab + bromfenac (DRUG), ranibizumab injection alone (DRUG).
Who is sponsoring clinical trial NCT00805233?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.